Febuxostat is the generic name of the new drug which was approved by the U.S. Food and Drug Administration on February 16. It is also called Uloric and Adenuric. You may not have heard anything about it yet as marketing approval was just granted April 21st.
It will be primarily used for people who have high levels of uric acid. It is considered more effective than allopurinol, but carries more risk of side effects.
The most comprehensive information comes from the European Medicines Agency at this link:
SparkPeople, SparkCoach, SparkPages, SparkPoints, SparkDiet, SparkAmerica, SparkRecipes, DailySpark, and other marks are trademarks of SparkPeople, Inc. All Rights Reserved.
SPARKPEOPLE is a registered trademark of SparkPeople, Inc. in the United States, European Union, Canada, and Australia. All rights reserved.